Anticancer Res 2010, 30:4959–4962.PubMed 25. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, PLX4032 mw Lingner J, Harley CB, Cech TR: Telomerase catalytic subunit homologs from fission yeast and human. Science 1997, 277:955–959.PubMedCrossRef 26. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997, 90:785–795.PubMedCrossRef 27. Yan P, Benhattar J, Coindre

JM, Guillou L: Telomerase activity and hTERT mRNA expression can be heterogeneous and does not correlate with telomere length in soft tissue sarcomas. Int J Cancer 2002, 98:851–856.PubMedCrossRef 28. Yan

P, Coindre JM, Benhattar J, Bosman FT, Guillou L: Telomerase activity and human telomerase reverse transcriptase mRNA expression in soft tissue tumors: correlation Tozasertib manufacturer with grade, histology, and proliferative activity. Cancer Res 1999, 59:3166–3170.PubMed 29. Matsuo T, Shimose S, Kubo T, Fujimori J, Yasunaga Y, Ochi M: Telomeres and telomerase in sarcomas. Anticancer Res 2009, 29:3833–3836.PubMed 30. Yang J, Yu Y, Duerksen-Hughes PJ: Protein kinases and their involvement in the cellular responses to genotoxic stress. Mutat Res 2003, 543:31–58.PubMedCrossRef 31. Dwyer J, Li H, Xu D, Liu JP: Transcriptional regulation of telomerase activity: roles of the the Ets transcription factor family. Ann N Y Acad Sci 2007, 1114:36–47.PubMedCrossRef 32. Goueli BS, Janknecht R: Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor. Selleck EPZ015938 Oncogene 2003, 22:8042–8047.PubMedCrossRef medroxyprogesterone 33. Nebreda AR, Porras A: p38 MAP kinases: beyond the stress response. Trends Biochem Sci 2000, 25:257–260.PubMedCrossRef 34. Ono K, Han J: The p38 signal transduction pathway: activation and function. Cell Signal 2000, 12:1–13.PubMedCrossRef 35. Neve RM,

Holbro T, Hynes NE: Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 2002, 21:4567–4576.PubMedCrossRef 36. Recio JA, Merlino G: Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 2002, 21:1000–1008.PubMedCrossRef 37. Pomérance M, Quillard J, Chantoux F, Young J, Blondeau JP: High-level expression, activation, and subcellular localization of p38-MAP kinase in thyroid neoplasms. J Pathol 2006, 209:298–306.PubMedCrossRef 38. Myatt SS, Redfern CP, Burchill SA: p38MAPK-Dependent sensitivity of Ewing’s sarcoma family of tumors to fenretinide-induced cell death. Clin Cancer Res 2005, 11:3136–3148.PubMedCrossRef 39. Halawani D, Mondeh R, Stanton LA, Beier F: p38 MAP kinase signaling is necessary for rat chondrosarcoma cell proliferation. Oncogene 2004, 23:3726–3731.